MAGALDRATE 400MG + SIMETHICONE 20MG ORAL SUSPENSION is a liquid pharmaceutical formulation containing Magaldrate and Simethicone as active components. The development of this combination requires careful control of particle dispersion, vehicle composition, viscosity and physical stability to maintain a uniform suspension throughout the product. Since the formulation contains dispersed solid material along with Simethicone, appropriate wetting, mixing and homogenization techniques may be required during manufacturing. For pharmaceutical companies developing a PCD Pharma Franchise portfolio, this oral suspension can be incorporated into a diversified liquid formulation range with standardized quality specifications and packaging.
The specified formulation contains Magaldrate 400 mg and Simethicone 20 mg in the finalized oral suspension. Magaldrate is incorporated as a dispersed pharmaceutical ingredient, while Simethicone requires appropriate dispersion within the liquid vehicle.
The formulation may contain suitable suspending agents, wetting agents, viscosity modifiers, sweeteners, flavours, preservatives and other pharmaceutical excipients depending on the final product design. Each excipient is selected according to its functional purpose and compatibility with the active ingredients.
Preformulation studies can be performed to evaluate particle-size distribution, bulk density, sedimentation behaviour, viscosity, pH and compatibility between the active ingredients and excipient system.
The vehicle must be designed to provide suitable physical stability while allowing the suspended material to remain adequately distributed after appropriate shaking. Formulation optimization therefore focuses on maintaining consistent rheological and dispersion characteristics throughout the intended storage period.
Uniform dispersion of Magaldrate is one of the important formulation considerations for MAGALDRATE 400MG + SIMETHICONE 20MG ORAL SUSPENSION. The particle characteristics of the solid component can influence sedimentation rate, viscosity and redispersibility.
Controlled wetting of the Magaldrate particles may be carried out before incorporation into the main vehicle. Wetting agents can be used where appropriate to reduce particle agglomeration and facilitate uniform dispersion.
Simethicone is incorporated through a controlled dispersion process suited to the selected formulation system. The order of addition, mixing speed and processing time are established during product development to achieve a homogeneous bulk preparation.
Suspending agents and viscosity modifiers may be hydrated or dispersed separately before being combined with the active components. Proper hydration can help develop the intended rheological structure of the final suspension.
Where suitable for the formulation, homogenization or controlled high-shear mixing may be considered to improve uniformity. Processing conditions should be optimized to minimize excessive foaming and unnecessary air incorporation.
Manufacturing begins with the verification of Magaldrate, Simethicone and all excipients against established raw-material specifications. The liquid vehicle is prepared in a suitable manufacturing vessel under controlled processing conditions.
Suspending agents, viscosity modifiers and other aqueous-phase components may be prepared separately according to the validated manufacturing sequence. Magaldrate is then gradually incorporated using controlled agitation to promote uniform wetting and dispersion.
Simethicone can be added at a defined stage based on the formulation design. Mixing conditions are maintained to achieve consistent distribution throughout the bulk without causing excessive aeration.
The finished bulk suspension may undergo suitable homogenization or other processing steps where required. After completion of manufacturing, the bulk product can be evaluated before being transferred to the filling stage.
In-process checks may include appearance, pH, viscosity, density, homogeneity and other relevant physical parameters. Monitoring these attributes during production helps identify deviations and supports batch-to-batch consistency.
Quality control of MAGALDRATE 400MG + SIMETHICONE 20MG ORAL SUSPENSION includes evaluation of the active ingredients as well as the overall physical properties of the finished product.
The formulation may be tested for appearance, colour, odour, pH, viscosity, density and fill volume. Sedimentation behaviour and redispersibility can also be evaluated to assess the physical performance of the suspension.
Appropriate analytical methods can be established for identification and quantitative determination of the relevant active components. Validated laboratory procedures help provide reliable results during finished-product testing and stability studies.
Uniformity of the suspension is particularly important because settling can occur during storage. The formulation should demonstrate acceptable redispersion characteristics according to predefined specifications.
Microbial quality is another important consideration for aqueous oral suspensions. Appropriate microbiological testing can be incorporated into the quality-control program according to the finalized product requirements.
Container compatibility can also be evaluated to ensure that the packaging material does not adversely affect the physical or chemical properties of the formulation.
Stability studies are conducted to evaluate how MAGALDRATE 400MG + SIMETHICONE 20MG ORAL SUSPENSION maintains its specified characteristics during storage. Depending on the finalized product specifications, stability parameters may include appearance, pH, viscosity, assay, sedimentation behavior, dispersibility and microbial quality.
Packaging selection should take into account the physical nature of the suspension and the need for practical dispensing. Pharmaceutical-grade bottles with compatible closures may be selected according to the product's formulation and stability requirements.
The container should support appropriate shaking and dispensing while maintaining adequate protection against environmental exposure. Closure compatibility and container-closure integrity can be evaluated during product development.
Stability studies should preferably assess the product in its final packaging configuration. This allows the manufacturer to evaluate potential interactions between the formulation and container materials throughout the proposed shelf life.
The resulting stability data can support the determination of suitable storage conditions and shelf-life specifications.
MAGALDRATE 400MG + SIMETHICONE 20MG ORAL SUSPENSION can be incorporated into a pharmaceutical company's liquid dosage-form portfolio alongside syrups, drops, dry suspensions and other oral formulations. Standardized composition, packaging and quality documentation can help maintain a consistent product catalogue.
For a PCD Pharma Franchise portfolio, the product can be presented with accurate composition, concentration, packing size, manufacturer details, storage information and other approved product particulars. Packaging artwork should correspond with the finalized formulation and applicable regulatory requirements.
The development of this oral suspension involves coordinated control of raw materials, particle dispersion, vehicle preparation, viscosity development, bulk mixing, homogenization where appropriate, filling and finished-product testing.
Overall, MAGALDRATE 400MG + SIMETHICONE 20MG ORAL SUSPENSION is a multi-component liquid formulation where controlled particle wetting, suspension stability and uniform Simethicone dispersion are important manufacturing considerations. Appropriate vehicle selection, rheological control, dispersibility assessment, analytical testing, microbial-quality evaluation, container compatibility and stability monitoring can support consistent product quality and effective integration into a professional pharmaceutical and PCD Pharma Franchise portfolio.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech